Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Entire DC Network
Serum Myostatin And Igf-1 As Biomarkers Of Sarcopenia: A Proof-Of-Concept Design, Ashley Binns
Serum Myostatin And Igf-1 As Biomarkers Of Sarcopenia: A Proof-Of-Concept Design, Ashley Binns
Graduate Theses and Dissertations
The population comprising older adults is growing exponentially, as are healthcare related costs. Nearly $20 billion is annually expensed by older adults for health-related issues affiliated with age-related decline in skeletal muscle mass. Yet, diagnostic criteria are not readily utilized in clinical practice. PURPOSE: Therefore, the purpose of this study was to provide evidence for use of blood biomarkers (myostatin, IGF-1) to predict appendicular skeletal muscle mass (ASM) among middle-aged and older adults. METHODS: A cross-sectional study was conducted among 106 individuals (n = 68 females; n = 38 males) aged ≥ 40 years of age (60.1 ± 11.1 y) …
Investigation Of The Effect Of Age On Regenerative Outcomes Following Treatment Of Volumetric Muscle Loss Injuries, John Taehwan Kim
Investigation Of The Effect Of Age On Regenerative Outcomes Following Treatment Of Volumetric Muscle Loss Injuries, John Taehwan Kim
Graduate Theses and Dissertations
Volumetric muscle loss (VML) is a traumatic injury in skeletal muscle resulting in the bulk loss of more than 20% of the muscle’s volume. Included in the bulk loss of muscle is the skeletal muscle niche comprised of nerve bundles, vasculature, local progenitor cells, basal lamina, and muscle fibers, overwhelming innate repair mechanisms. The hallmark of VML injury is the excessive accumulation of non-contractile, fibrotic tissue and permanent functional deficits. Though predominant in the younger demographic, the elderly population is also captured within VML injuries. There are many factors that change with aging in skeletal muscle that may further hinder …